The US Food and Drug Administration (FDA) has approved Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who ...

Huabo Biopharm (Shanghai) (Huabobio), a subsidiary of Shanghai Huaota Biopharmaceutical Co Ltd, is a pharmaceutical company that develops and markets therapies for the treatment of cancer. The company ...

HB-0025 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Renal Cell Carcinoma.

This includes skin cancers like the following: Basal cell carcinoma (BCC) is the most common type of skin cancer. It starts in the top layer of the skin in cells called basal cells. Squamous cell ...

Department of Oral Anatomy and Physiology, Jilin Provincial Key Laboratory of Oral Biomedical Engineering, Hospital of Stomatology, Jilin University, Changchun, China Oral squamous cell carcinoma ...

Histologic Features. Squamous cell carcinoma is comprised of proliferating malignant squamous cells with increased mitotic activity. In invasive SCC, tumor cells are seen below the epidermis.

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

As per the findings of the CheckMate 577 trial, patients with esophageal cancer (EC) who had neoadjuvant chemoradiation with residual pathologic disease should be considered adjuvant immunotherapy ...

Oral lichen planus with ulceration must be followed meticulously to prevent the development of oral squamous cell ... risk of oral squamous cell carcinoma in ulcerative lichen planus.

The FDA has approved cosibelimab, a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. It is the first and only PD-L1 blocker approved to treat ...